Quick Answer
Actinium Pharmaceuticals, Inc. reported Net Income of -$33.89 million for fiscal year 2025.
Actinium Pharmaceuticals, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$33.89M | +11.4% |
| 2024 | -$38.24M | +21.7% |
| 2023 | -$48.82M | -47.9% |
| 2022 | -$33.02M | -33.3% |
| 2021 | -$24.77M | -11.5% |
| 2020 | -$22.21M | -1.4% |
| 2019 | -$21.90M | +7.4% |
| 2018 | -$23.65M | +11.1% |
| 2017 | -$26.60M | -9.4% |
| 2016 | -$24.32M | -15.7% |
| 2015 | -$21.03M | +14.8% |
| 2014 | -$24.69M | -129.1% |
| 2013 | -$10.77M | -28.9% |
| 2012 | -$8.36M | -142.7% |
| 2011 | -$3.44M | -637.2% |
| 2010 | -$467.3K | +86.4% |
| 2009 | -$3.43M | +38.5% |
| 2008 | -$5.57M | +0.8% |
| 2007 | -$5.62M | +7.2% |
| 2006 | -$6.05M | -32.2% |
| 2005 | -$4.58M | +20.1% |
| 2004 | -$5.73M | -62.4% |
| 2003 | -$3.53M | -10.6% |
| 2002 | -$3.19M | +37.3% |
| 2001 | -$5.09M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$5.13M | +55.6% | +25.4% |
| June 30, 2025 | -$6.88M | +39.4% | +56.8% |
| March 31, 2025 | -$15.94M | -83.8% | -37.8% |
| September 30, 2024 | -$11.57M | +12.9% | -1.9% |
| June 30, 2024 | -$11.35M | +25.2% | -30.9% |
| March 31, 2024 | -$8.67M | +21.4% | +34.7% |
| September 30, 2023 | -$13.28M | -40.1% | +12.5% |
| June 30, 2023 | -$15.18M | -95.5% | -37.5% |
- Actinium Pharmaceuticals, Inc. showed an increase of +11.4% in Net Income compared to the prior fiscal year.
- Over the 2001–2025 period, Actinium Pharmaceuticals, Inc.’s net income has declined by 565.7% (from -$5.09 million to -$33.89 million).
- The most recent figure is from Actinium Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: